239 / 1195
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in
medically inoperable stage I NSCLC
J. Nyman
1
, A. Hallqvist
1
, J.A. Lund
2
, O.T. Brustugun
3
, P. Bergström
4
, S. Friesland
5
, R.
Lewensohn
5
, N. Drugge
6
, H. Rylander
1
, I. Lax
7
102 patients, (T1-2N0M0) NSCLC,
significant comorbidity
9 Scandinavian centers
rando: SBRT 3x 22 Gy; CFRT 35x 2 Gy
primary endpoint: freedom from
progression at 3 years
PFS at 36 mths:
61.1% SBRT
56.8 % CFRT
OS SBRT: 72 %, 65 % and 34 %
OS CFRT: 84 %, 62 % and 34 %
median survival: 41.3 vs. 42.1 months,
Toxicity grade ≥ 3
SBRT 18 %, CFRT 16 %
Any pneumonitis 16 % vs. 34 % in
15 · 22. Januar 2016
Conclusion: There was a tendency to improved disease control rate at three
years for the SBRT patients with similar overall survival and less toxicity
compared to the conventional arm.
SBRT is much more convenient for the patient and more cost effective and
should be considered standard treatment for inoperable patients with stage I
NSCLC